Revenue
2022
2023
2024
2025
CNS Pharmaceuticals, Inc. (CNSP)
Price$5.73Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — |
| Research & development | $9.8M | $9.3M | $14.1M | $9.3M | $9.8M | $5.1M | $1.9M | $21,267 |
| Operating expenses | $16.0M | $14.9M | $18.9M | $15.3M | $14.5M | $9.5M | $3.8M | $881,787 |
| Operating income | −$16.0M | −$14.9M | −$18.9M | −$15.3M | −$14.5M | −$9.5M | −$3.8M | −$881,787 |
| EBITDA | −$16.0M | −$14.9M | −$18.9M | −$15.3M | −$14.5M | −$9.4M | −$3.8M | −$881,787 |
| Net income | −$15.9M | −$14.9M | −$18.9M | −$15.3M | −$14.5M | −$9.5M | −$3.9M | −$7.4M |
| Basic EPSper basic share | -$35.75 | -$466.89 | -$150,000.00 | -$336,600.00 | -$495,000.00 | -$17,100.00 | -$8,400.00 | -$21,000.00 |
| Diluted EPSper diluted share | -$35.75 | -$466.89 | -$150,000.00 | -$336,600.00 | -$495,000.00 | -$17,100.00 | -$8,400.00 | -$21,000.00 |
Owners
Reported shareholders
≈39.23%of listed shares
Cortice Biosciences, Inc.573.37K shares · Jul 30, 2024
View holders
| Holder | % owned |
|---|---|
Cortice Biosciences, Inc. | ≈39.23%573.37K shares |
Ikarian Capital, LLC | 9.29%135.83K shares |
ADAR1 Capital Management, LLC | 4.79%70K shares |
Stonepine Capital Management, LLC | 2.84%41.57K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 0.93%13.52K shares |
VANGUARD FIDUCIARY TRUST CO | 0.70%10.23K shares |
Charles Faith L. | ≈0.49%7.1K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.48%6.99K shares |
UBS Group AG | 0.10%1.46K shares |
Tower Research Capital LLC (TRC) | 0.05%799 shares |
BARCLAYS PLC | <0.01%19 shares |
BARRETT & COMPANY, INC. | <0.01%8 shares |
DANSKE BANK A/S | <0.01%1 shares |
Percentages use 1.46M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4 | Charles Faith L.Director | BuyCommon Stock | 7.1K | $4.79 | $34.0K | 7.1K |